MABS-01 / Manhattan BioSolutions - LARVOL DELTA

Development of potent FGFR4-targeted antibody-drug conjugate therapies for rhabdomyosarcoma and other cancers expressing FGFR4 (AACR 2025) - "3A11 was internalized by FGFR4-positive cells and the internalization efficiency was significantly correlated with FGFR4 surface expression levels. Both ADCs selectively killed FGFR4-expressing cells, with their potency correlating with FGFR4 expression and 3A11 internalization. Western blot confirmed that 3A11-MMAE induced specific apoptosis and 3A11-Exatecan induced cell death after DNA damage in FGFR4-expressing RMS cells."

Breast Cancer • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • CTSC • FGFR4 • LGMN

A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4 (AACR 2024) - "Mice treated with one cycle of 3A11-vc-MMAE (3mg/kg twice a week for 2 weeks) demonstrated a significantly increased survival rate of 30% for the RH4 model with a median survival of 43 days for 3A11-vc-MMAE and 23 days for control, vehicle-treated mice (p-value = 0.0038), and 70% for the RMS559 model, with a median survival not reached for of 3A11-vc-MMAE treated compared with 23 days for control mice (p-value < 0.0001). Of note, tumors were eradicated in 4 out of 10 mice bearing RMS559 xenografts.Conclusions and Future Directions Our results demonstrate that the ADC 3A11-vc-MMAE provides a potent and specific precision immunotherapy for rhabdomyosarcoma and other cancers with a high expression of FGFR4, which warrants further development for clinical translation."

Clinical • IO biomarker • Late-breaking abstract • Breast Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • FGFR4